Literature DB >> 6178487

Serological characterization of strains of Moraxella bovis using double immunodiffusion.

C Gil-Turnes, F L de Araujo.   

Abstract

Sera were produced in rabbits against nine Moraxella bovis strains isolated in Brazil and three in the United States. Antigens were prepared for double immunodiffusion tests by thawing concentrated suspensions of the strains. Sera were tested against homologous and heterologous antigen preparations by the double immunodiffusion method. Sera showing precipitin bands with heterologous antigens were absorbed. Antigenic differences were detected between the strains and a provisional grouping of strains of M. bovis was suggested on the basis of antigenic composition. Differences between isolates from different geographical locations were found and some strains appeared antigenically more complex than others. The relevance of this work to vaccine production was suggested.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6178487      PMCID: PMC1320273     

Source DB:  PubMed          Journal:  Can J Comp Med        ISSN: 0008-4050


  12 in total

1.  Experimentally induced infections bovine keratoconjunctivitis: effectiveness of a pilus vaccine against exposure to homologous strains of Moraxella bovis.

Authors:  G W Pugh; D E Hughes; G D Booth
Journal:  Am J Vet Res       Date:  1977-10       Impact factor: 1.156

Review 2.  Infectious bovine keratoconjunctivitis: a review.

Authors:  P J Baptista
Journal:  Br Vet J       Date:  1979 May-Jun

3.  Experimental bovine infectious keratoconjunctivitis caused by sunlamp irradiation and Moraxella bovis infection: resistance to re-exposure with homologous and heterologous Moraxella bovis.

Authors:  D E Hughes; G W Pugh; T J McDonald
Journal:  Am J Vet Res       Date:  1968-04       Impact factor: 1.156

4.  Inhibition of autoagglutination of Moraxella bovis by 10 per cent magnesium chloride.

Authors:  G W Pugh; D E Hughes
Journal:  Appl Microbiol       Date:  1970-01

5.  Pili as a mediator of the attachment of gonococci to human erythrocytes.

Authors:  T M Buchanan; W A Pearce
Journal:  Infect Immun       Date:  1976-05       Impact factor: 3.441

6.  K99 surface antigen of Escherichia coli: purification and partial characterization.

Authors:  R E Isaacson
Journal:  Infect Immun       Date:  1977-01       Impact factor: 3.441

7.  Composition and molecular weight of pili purified from Pseudomonas aeruginosa K.

Authors:  L S Frost; W Paranchych
Journal:  J Bacteriol       Date:  1977-07       Impact factor: 3.490

8.  Antigenic characterisitcs of Moraxella nonliquefaciens fimbriae in double immunodiffusion.

Authors:  L O Frøholm
Journal:  Acta Pathol Microbiol Scand B       Date:  1978-08

9.  Bovine infectious keratoconjunctivitis: serological aspects of Moraxella bovis infection.

Authors:  G W Pugh; D E Hughes; T J McDonald
Journal:  Can J Comp Med       Date:  1971-04

10.  Serologic response of vaccinated cattle to strains of Moraxella bovis isolated during epizootics of keratoconjunctivitis.

Authors:  G W Pugh; D E Hughes; G D Booth
Journal:  Am J Vet Res       Date:  1978-01       Impact factor: 1.156

View more
  4 in total

1.  Hemagglutination, autoagglutination and pathogenicity of Moraxella bovis strains.

Authors:  C Gil-Turnes
Journal:  Can J Comp Med       Date:  1983-10

2.  Serotypes and antibiotic sensitivity of Moraxella bovis isolated from an outbreak of infectious bovine keratoconjunctivitis.

Authors:  C Gil-Turnes; I M Albuquerque
Journal:  Can J Comp Med       Date:  1984-10

3.  Moraxella bovis hemagglutinins: effect of carbohydrates, heating and erythrocytes.

Authors:  C Gil-Turnes; G A Ribeiro
Journal:  Can J Comp Med       Date:  1985-01

4.  Antigenic relationships of Moraxella bovis isolates recovered from outbreaks of infectious bovine keratoconjunctivitis in Argentina, Brazil, and Uruguay between 1983 and 2000.

Authors:  Fabrício Rochedo Conceição; Fernando Paolicchi; Ana Lia Cobo; Carlos Gil-Turnes
Journal:  Can J Vet Res       Date:  2003-10       Impact factor: 1.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.